Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

How to stop the ASX decline? ASIC and investors have some radical ideas

Addressing the ASX decline is a question that has been considered for many months now. In 2023-24, more companies left the ASX in the past 2 years than any 2 year period since the 1990s recession - whether being brought out by private equity or a big industry player, delisting to a penny stock exchange…

ByNick SundichJune 6, 2025

Here’s why investors in health insurance stocks like Medibank and NIB should stay alert

Health insurance stocks are facing a big dilemma right now. On one hand patients don't want to pay more, but private hospitals want them to pay more. What's new about that, you might ask? Well, the collapse of Healthscope has bought this issue to the forefront, and something will have to give sooner or later. Of…

ByNick SundichJune 5, 2025

Investing in IPOs (Initial Public Offerings) in 2025: Here’s what investors need to know

Investing in IPOs offers the opportunity for investors to make gains they couldn't make with any other company, but also offer a risk of making significant losses which you may not be able to recoup. They're also a major milestone for companies involved, as they not only provide access to significant amounts of capital but…

ByNick SundichJune 3, 2025

Proteomics’ PromarkerD test for DKD has been launched in Australia, and two more tests will launch later in 2025

2025 has been, and will continue to be, a big year for Proteomics, which has just launched PromarkerD onto the Australian market. Before this year is over, the company anticipates launching another 2 tests - PromarkerEndo and PromarkerEso; and is eyeing off the US market too. Recap of Proteomics (ASX:PIQ) For investors that are new to…

ByNick SundichMay 28, 2025

Will Ozempic hurt healthcare stocks? Here are 5 reasons we don’t think so

Will Ozempic hurt healthcare stocks? Investors who've been selling healthcare stocks left right and centre - except Novo Nordisk of course, now the largest stock in Europe by market capitalisation - believe it will. But even though we hear these arguments loud and clear, we think these fears are overblown. Ozempic is a weight-loss drug that…

ByNick SundichMay 28, 2025

ESG Investing in 2025: How can I tell if a stock or fund is ethical or ESG compliant?

ESG investing is becoming increasingly popular with investors. But as this happens, it begs the question as to just how you can tell if an applicable stock or fund is ESG friendly? So how can I tell if my stock or fund is ESG compliant? As tough as it is to disappoint our readers, there is no…

ByNick SundichMay 26, 2025

Immutep (ASX:IMM): Set to commercialise its lung cancer treatment by 2027

Developing a cancer drug is a long journey, but Immutep (ASX:IMM) is more towards the end than the start. A few months ago, when it received its latest capital injection (of $100m), the company told its investors it was less than three years away from commercialising its cancer drug. Immutep's share price may not suggest it…

ByNick SundichMay 7, 2025

This Phase 3 ASX biotech is on the brink of unlocking market opportunities worth a cumulative US$9.1bn

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) is a Phase 3 ASX biotech that is close to unlocking its market opportunity. It is expecting to complete its Phase 3 trials during FY26 (the 12 months starting on July 1, 2025), and success here would lead to unlocking of market opportunities worth a cumulative US$9.1bn. Specifically, the global DFI…

ByNick SundichMay 6, 2025

Warren Buffett is retiring, will hand the top job at Berkshire to Greg Abel by the end of 2025. Here’s what you need to know

After many decades at the helm of Berkshire Hathaway, Warren Buffett is retiring. After founding his empire in 1965, he built it into a US$1tn+ empire owning many of America's best companies and profiting off them. But of course, all good things must come to an end - at least a tenure led by the…

ByNick SundichMay 5, 2025

Kidney disease-focused biotech Dimerix announced a US licensing deal for DMX-200! And this could be the best deal of all!

Dimerix has been targeting a US licensing deal for DMX-200 and the dreams are now a reality as of this morning! The company already had licensing deals with 2 companies for other jurisdictions, but not for the US (or China) which were and are larger opportunities. But this morning, it unveiled the deal to shareholders…

ByNick SundichMay 1, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

How to stop the ASX decline? ASIC and investors have some radical ideas

Here’s why investors in health insurance stocks like Medibank and NIB should stay alert

Investing in IPOs (Initial Public Offerings) in 2025: Here’s what investors need to know

Proteomics’ PromarkerD test for DKD has been launched in Australia, and two more tests will launch later in 2025

Will Ozempic hurt healthcare stocks? Here are 5 reasons we don’t think so

ESG Investing in 2025: How can I tell if a stock or fund is ethical or ESG compliant?

Immutep (ASX:IMM): Set to commercialise its lung cancer treatment by 2027

This Phase 3 ASX biotech is on the brink of unlocking market opportunities worth a cumulative US$9.1bn

Warren Buffett is retiring, will hand the top job at Berkshire to Greg Abel by the end of 2025. Here’s what you need to know

Kidney disease-focused biotech Dimerix announced a US licensing deal for DMX-200! And this could be the best deal of all!

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here